NCT04097301View on ClinicalTrials.gov

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 27, 2019

Primary Completion Date

June 18, 2021

Study Completion Date

June 18, 2021

Conditions
Acute Myeloid LeukemiaMultiple Myeloma
Interventions
DRUG

MLM-CAR44.1 T-cells at day 0 Single intravenous infusion

Lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3.

Trial Locations (3)

Unknown

Department of Haematooncology, Fakultni Nemocnice, Ostrava

IRCCS San Raffaele, Milan

IRCCS Ospedale Pediatrico Bambino Gesù, Roma

Sponsors
All Listed Sponsors
collaborator

Horizon 2020 - European Commission

OTHER

lead

AGC Biologics S.p.A.

INDUSTRY